Cargando…

Elotuzumab spares dendritic cell integrity and functionality

Detalles Bibliográficos
Autores principales:	Schlaweck, Sebastian, Strauss, Leon, Daecke, Solveig, Brossart, Peter, Heine, Annkristin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164573/ https://www.ncbi.nlm.nih.gov/pubmed/33651141 http://dx.doi.org/10.1007/s00432-021-03572-z

Ejemplares similares

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function
por: Heine, Annkristin, et al.
Publicado: (2015)

Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer
por: Heine, Annkristin, et al.
Publicado: (2023)

Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report
por: Koerber, Ruth-Miriam, et al.
Publicado: (2021)

Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma
por: Koerber, Ruth-Miriam, et al.
Publicado: (2015)

SARS-CoV-2 PrEP complicates antibody testing after vaccination: a call for awareness
por: Monin, Malte B., et al.
Publicado: (2022)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Clinical and immunological effects of mRNA vaccines in malignant diseases
por: Heine, Annkristin, et al.
Publicado: (2021)

Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning
por: Wolf, Dominik, et al.
Publicado: (2014)

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
por: Suzuki, K, et al.
Publicado: (2017)

Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)

Two cases of EBV infection preceding lymphoma
por: Saal, Jonas, et al.
Publicado: (2022)

Elotuzumab for multiple myeloma
Publicado: (2022)

Dexamethasone induced inhibition of Dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways
por: Kotthoff, Philipp, et al.
Publicado: (2017)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells
por: De Magis, Alessio, et al.
Publicado: (2021)

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

G-quadruplexes: a promising target for cancer therapy
por: Kosiol, Nils, et al.
Publicado: (2021)

RNA Vaccines in Cancer Treatment
por: Bringmann, Anita, et al.
Publicado: (2010)

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
por: Gentile, Massimo, et al.
Publicado: (2020)

Baseline immune signature score of Tregs × HLA-DR(+)CD4(+) T cells × PD1(+)CD8(+) T cells predicts outcome to immunotherapy in cancer patients
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)

Mechanisms of Action and Clinical Development of Elotuzumab
por: Ritchie, David, et al.
Publicado: (2017)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu, Yi-Chang, et al.
Publicado: (2014)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma
por: Fancher,(1,2), Karen M., et al.
Publicado: (2016)

The sparing phenomenon of cutaneous amyloidosis
por: Zhou, Hui-Wen, et al.
Publicado: (2021)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

In Spare Moments
Publicado: (1889)

Carbon fiber couches and skin sparing
por: Court, Laurence, et al.
Publicado: (2010)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab
por: Chen, Wei-Chih, et al.
Publicado: (2017)

Anaesthetic consideration for robotic nipple sparing mastectomy
por: Mittal, Amit Kumar, et al.
Publicado: (2017)

COVID-19 in Nigeria: Is the pharmaceutical sector spared?
por: Akande-Sholabi, Wuraola, et al.
Publicado: (2020)

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
por: Wang, Huihan, et al.
Publicado: (2021)

Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE
por: Humbel, Morgane, et al.
Publicado: (2021)

Tumor rejection in Cblb(−/−) mice depends on IL-9 and Th9 cells
por: Schanz, Oliver, et al.
Publicado: (2021)

Dose sparing of opioids and anaesthetics with pre-operative dexmedetomidine
por: Saikia, Priyam
Publicado: (2013)

MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation
por: Stickel, Natalie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1haav02s7usicb1i0i01rsts4v